Compare NextEra Energy, Inc. (NEE) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Tango Therapeutics Inc. — how do they compare? NextEra Energy, Inc. trades at $79.23 (market cap $163.48B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: NextEra Energy, Inc. is far larger — about 43.7× Tango Therapeutics Inc.'s market cap, and NextEra Energy, Inc. pays a 3.18% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NextEra Energy, Inc. for 83 Days and Tango Therapeutics Inc. for 0 Days on average.
| NEE | TNGX | |
|---|---|---|
Market Cap | $163.48B | $3.74B |
Volume | 11,050,036 | 3,438,781 |
Sector | Utilities | Health |
52-Week High | $97.88 | $32.90 |
52-Week Low | $75.49 | $7.50 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $270.81B | $2.76B |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $78.22, down 0.37% on the day, with a bullish technical signal despite mixed indicators. The stock shows strong fundamentals with a P/E of 17.58, net income margin of 32.4%, and recent earnings beats in Q1 and Q2 2026. Recent news highlights growth initiatives, including a $22.3 billion energy infrastructure project in Texas, positioning the company for expansion amid a 66.66% analyst buy rating.
Outlook remains positive with a consensus price target of $95.60, offering ~22% upside. Key risks include rising debt-to-asset ratios (47.6% in 2025) and interest rate sensitivity. Investors should weigh strong profitability against capital expenditure demands and macroeconomic pressures.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
